Ipilimumab (IPI) vs placebo (PBO) after complete resection of stage III melanoma: Final overall survival results from the EORTC 18071 randomized, double-blind, phase 3 trial Meeting Abstract
| Authors: | Eggermont, A. M. M.; Chiarion-Sileni, V.; Grob, J. J.; Dummer, R.; Wolchok, J. D.; Schmidt, H.; Hamid, O.; Robert, C.; Ascierto, P. A.; Richards, J. M.; Lebbe, C.; Ferraresi, V.; Smylie, M.; Weber, J. S.; Taitt, C.; de Pril, V.; de Schaetzen, G.; Suciu, S.; Testori, A. |
| Abstract Title: | Ipilimumab (IPI) vs placebo (PBO) after complete resection of stage III melanoma: Final overall survival results from the EORTC 18071 randomized, double-blind, phase 3 trial |
| Meeting Title: | 41st European Society for Medical Oncology Congress (ESMO) |
| Journal Title: | Annals of Oncology |
| Volume: | 27 |
| Issue: | Suppl. 6 |
| Meeting Dates: | 2016 Oct 7-11 |
| Meeting Location: | Copenhagen, Denmark |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2016-10-01 |
| Start Page: | vi574 |
| Language: | English |
| ACCESSION: | WOS:000393913000724 |
| DOI: | 10.1093/annonc/mdw435.35 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: LBA2_PR -- Source: Wos |
